Clinical Trial Update: Second Line Treatment With Nal-IRI and S1 in Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update studying nal-IRI combined with S1 as second-line therapy for metastatic pancreatic cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Nal-IRI (nanoliposomal irinotecan)
• S1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Conditions: Metastatic Pancreatic Cancer | Phase 2 | Status: UNKNOWN